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A CONTROLLED, PROSPECTIVE LONGITUDINAL, INTERVENTIONAL, 
NATURALISTIC STUDY TO EVALUATE THE UNIQUE HEALTH CARE 
PROGRAM “CONVERSATION MAP©” FOR TURKISH PATIENTS WITH 
TYPE-2 DIABETES IN ONE GERMAN MAJOR CITY
Korolewa V, Kretschmer B, Clouth J
Lilly Deutschland GmbH, Bad Homburg, Germany
OBJECTIVES: Considering a cultural and epidemiological disparity between Turkish 
and German type-2 diabetes patients in Germany, resulting in a health care gap, a 
customised diabetes program for Turkish migrants is required. The objective was to 
evaluate “Conversation Map©”, a unique health care education program for Turkish 
migrants with type-2 diabetes in Germany. METHODS: Ninety-two Turkish patients 
with poor German language skills were divided into interventional (IV, n = 44) and 
control (C, n = 48) groups, 42 German (G) patients served as additional control group. 
The IV group attended a structured once weekly, 2 hr “Conversation Map©” training 
over 4 weeks in Turkish language. The two control groups had no intervention. 
Sociodemographic data were recorded at baseline, and standardized questionnaires 
assessing treatment, diabetes-knowledge (0–6; 6 = everything right), and therapy 
adherence (“Essential Training Content (ETC)” 0–10; 10 = best) were applied at 
baseline and after 4 weeks after training in the IV group. Baseline differences between 
the groups and changes of data after 4 weeks compared to baseline were tested (paired 
t-test, α = 0.05, two-sided). RESULTS: Ethnic groups were comparable on demo-
graphic data, whereas Turkish patients had lower education level (P < 0.001). 55% 
of all Turkish patients (IV and C) were insulin-dependent and 63% were previously 
not attending any diabetes-training. Baseline diabetes knowledge of Turkish patients 
was signiﬁ cantly lower than in the German control group (IV 2.38, T 2.77, G: 4.10, 
P < 0.001), as well as the ETC score (IV 6.37, C 5.92, G 7.98, P < 0.001). After 
“Conversation Map©” training the Turkish group achieved signiﬁ cantly higher mean 
knowledge- and ETC-score values compared to baseline (difference +70%, ETC: 
+25%, P < 0.001) and were comparable to the German group. CONCLUSIONS: The 
study demonstrated that the cultural sensitive training “Conversation Map©”, led to 
a signiﬁ cant increase of disease-knowledge and therapy adherence, helping to improve 
the health care situation of Turkish patients, with cost savings potential in the long 
term.
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TIME TO ADD-ON MEDICATION USE FOR PATIENTS WITH TYPE 2 
DIABETES MELLITUS (T2DM) WHO FAILED METFORMIN 
MONOTHERAPY
Qiu Y1, Fu AZ2, Radican L1
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OBJECTIVES: Add-on medications are recommended if target glycemic goals for 
patients with T2DM are not achieved or sustained after initial metformin mono-
therapy. This study examined the time to add-on medication use after metformin 
monotherapy failure in clinical practice. METHODS: Selected from a large US EMR 
database between Janujary 1, 1997 and December 31, 2008, included patients had to 
be aged ≥18 years with a diagnosis of T2DM who had HbA1c ≥ 7.0% or ≥ two fasting 
blood glucose levels of 126 mg/dL or greater. Treatment failure was deﬁ ned as HbA1c 
≥ 7% (index date) after metformin monotherapy for at least 6 months. Baseline data 
were extracted during 1 year prior to the index date. Time to add-on medication use 
was time between index date to the ﬁ rst add-on medication use during follow-up and 
was evaluated for the overall cohort and for three index HbA1c subgroups: <8%, 
8–9%, and >9%. a Cox proportional hazard model was employed to determine 
baseline clinical and demographic characteristics associated with shorter time to 
add-on medication use. RESULTS: There were 12,566 patients meeting the inclusion 
criteria; 8656, 2175 and 1735 had index HbA1c < 8%, 8–9% and >9%, respectively. 
The overall mean (SD) age was 63 (12) years and 51% were female. The median time 
to add-on medication use was 15.7 months overall and 17.0, 13.9 and 11.3 months 
for patients with index HbA1c < 8%, 8–9% and >9%, respectively. Higher index A1c, 
greater body mass index, higher Charlson comorbidity index, younger age, males, 
lower LDL were signiﬁ cantly associated with shorter time to add-on medication use 
(all P < 0.05). CONCLUSIONS: This indicates, in US clinical practice, it takes over 
a year for a diabetic patient who has suboptimal glycemic level after initial metformin 
monotherapy to receive add-on medications. There is room through disease manage-
ment so that patients who have failed metformin monotherapy, if eligible and appro-
priate, receive add on therapy sooner rather than later.
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OBJECTIVES: To evaluate the prescribed daily dose of liraglutide for patients in 
German statutory health insurances. The novel once-daily incretin analogue, liraglu-
tide, mimics the effect of endogenous glucagon-like peptide 1 (GLP-1). Liraglutide was 
launched in Germany in July 2009 in a device allowing 3 different dosages (0.6 mg 
for initial titration; and the two maintenance doses 1.2 and 1.8 mg). The deﬁ ned daily 
dose (DDD) was set by WHO at 1.2 mg. The prescribed daily dose (PDD) has not 
been evaluated so far. METHODS: Sampled data from German statutory health 
insurances (SHI) was provided by Insight Health (patient tracking data) for the period 
from July 2009 to March 2010 (9 months) covering about 11% of all patients in 
German SHI. All patients with prescriptions of liraglutide were identiﬁ ed (n = 4,284). 
Patients with only one prescription and less than 4 weeks between ﬁ rst and last date 
of prescription were excluded to avoid overrepresented inﬂ uence of low dosed therapy 
starters (remaining patients: n = 2,118). Total number of prescribed pens was deter-
mined from ﬁ rst to second last prescription and total consumption in mg was calcu-
lated. Number of days between ﬁ rst and last prescription was determined and mean 
average consumption in mg per day was calculated. RESULTS: The mean PDD of 
liraglutide in 2118 patients was 1.28 mg. Sensitivity analyses including only patients 
with longer periods of use showed decreasing average consumption; patients with at 
least 10 weeks duration of treatment showed a mean daily dose of 1.25 mg. Stocking 
effects (prescription before package is empty) could have driven the increase in average 
use in the starting period and at the end of the calendar year. CONCLUSIONS: The 
longer patients use liraglutide the lower the observed PDDs. The DDD of 1.2 mg is a 
valid estimate for real life usage of liraglutide.
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TIME TO TREATMENT MODIFICATION AMONG PATIENTS WITH TYPE 
2 DIABETES WHO INITIATED EXENATIDE OR INSULIN GLARGINE
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OBJECTIVES: To examine time to treatment modiﬁ cation for patients with type 2 
diabetes (T2D) initiating treatment with exenatide BID or insulin glargine. METHODS: 
A retrospective analysis was conducted using the Thomson Reuters Research Data-
bases. Adult patients with T2D who initiated exenatide (N = 9197) or glargine (N = 
4499) between October 1, 2006 and September 30, 2007 with 12 months pre- and 
18 months post-index continuous enrollment were included. Treatment modiﬁ cation 
was deﬁ ned as the ﬁ rst event of change in the treatment and was classiﬁ ed further into 
three types: intensiﬁ cation, switching or discontinuation of the index medication. The 
2 cohorts were 1:1 propensity score matched on baseline demographics, clinical 
characteristics, and prior health care utilization. Survival analysis was used to examine 
time to treatment modiﬁ cation. RESULTS: Propensity score matching resulted in 
inclusion of 3774 exenatide and 3774 glargine patients with a mean age of 57 years, 
mean Deyo Charlson Comorbidity Index score of 1.6, and with proportionately more 
males (54%) than females. All of the patients concomitantly used a non-index antidia-
betes medication in post-index period. The 18-month discontinuation rates were 
38.3% and 40.0% (P = 0.14) and the treatment intensiﬁ cation rates were 15.9% and 
26% (P < 0.0001) for exenatide and glargine, respectively. Alternatively, 14.9% of 
exenatide-treated patients switched therapies, compared to 10.0% of glargine-treated 
patients (P < 0.0001). Glargine-treated patients were 33% more likely to modify 
treatment than exenatide-treated patients (Hazard Ratio (HR): 1.33, P < 0.0001). 
Glargine-treated patients were 72% more likely to intensify their treatment (HR = 
1.72, P < 0.0001), 25% more likely to discontinue (HR = 1.25, P < 0.0001), and 29% 
less likely to switch to new therapy (HR = 0.71, P < 0.0001) compared to exenatide. 
CONCLUSIONS: This analysis showed that exenatide-treated patients were less likely 
to modify their treatment suggesting potential longer durability with exenatide 
therapy. Furthermore, exenatide-treated patients were less likely to discontinue or 
intensify but more likely to switch their treatment than glargine-treated patients.
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OBJECTIVES: The goal of treating acromegaly is directed at removing the tumor, 
preventing tumor re-growth and reducing long-term morbidity and mortality. For this 
purpose, different health resources are necessary. This study evaluates the disease 
resources and costs in Spain. METHODS: An epidemiological, prospective, natural-
istic, multicentric study (30 endocrinologists) involving acromegalic patients with 
micro (≤10 mm) or macro (>10 mm) adenomas was performed. Patients were catego-
rised as Surgical Group (SG) (surgery in the 6 months before inclusion or during 
follow-up period and somatostatin analogue (SA) treatment for <6 months during the 
pre-surgery period) and Medical Treatment Group (MTG) (patients receiving SA 
treatment for ≥6 months, with/without surgery following SA treatment). Resource data 
were collected from standard visits during a 2-years period. RESULTS: The study 
included 74 patients (56 SG and 18 MTG). Most patients were women (62%). The 
mean (SD) age was 49 (14) years. The annual direct acromegaly cost per patient is 
c9668 (c9223 SG vs. c11,054 MTG). The cost of illness was higher in patients with 
macroadenoma than in microadenoma (c11,053 vs. c5809), and it is increased in 
young patients (<40 years). Surgical procedures in acromegaly (involving hospitaliza-
tion and complementary tests) constitute the 22% and 8% of the illness cost in SG 
